MAPT and Alzheimer disease: This study assessed simulated digestive fractions (representing potentially directly absorbed metabolites) and gut microbiota-derived metabolites resulting from gut microbiota metabolism (via human fecal fermentation) from these MB for their capacity to modulate ROS production in human microglial cells (HMC3) and to counteract Tau- and Aβ-induced toxicity in transgenic C. elegans models of AD.